

CITATION REPORT

List of articles citing

SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEAR

DOI: 10.1016/s0022-5347(05)67140-6
Journal of Urology, 2000, 164, 1197-1200.

Source: <https://exaly.com/paper-pdf/32243159/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
59	SILDENAFIL VERSUS THE VACUUM ERECTION DEVICE: PATIENT PREFERENCE. <i>Journal of Urology</i> , 2001 , 166, 1779-1781	2.5	34
58	Prognostic factors for response to sildenafil in patients with erectile dysfunction. <i>European Urology</i> , 2001 , 40, 641-6; discussion 647	10.2	76
57	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. <i>Current Opinion in Urology</i> , 2001 , 11, 625-30	2.8	2
56	Current World Literature. <i>Current Opinion in Urology</i> , 2001 , 11, 637-656	2.8	
55	Current treatments and emerging therapeutic approaches in male erectile dysfunction. <i>BJU International</i> , 2001 , 88 Suppl 3, 11-7	5.6	21
54	Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. <i>International Journal of Impotence Research</i> , 2002 , 14, 38-43	2.3	34
53	Intracavernous injection as an option for aging men with erectile dysfunction. <i>Aging Male</i> , 2002 , 5, 177-180		
52	Management of Erectile Dysfunction. <i>Disease Management and Health Outcomes</i> , 2002 , 10, 431-452		5
51	[Efficacy and safety of sildenafil in patients with erectile dysfunction and hypertension. Prognostic factors]. <i>Medicina Clínica</i> , 2002 , 119, 281-5	1	4
50	UK department of health guidance on prescribing for impotence following the introduction of sildenafil: potential to contain costs in the average health authority district. <i>Pharmacoeconomics</i> , 2002 , 20, 839-46	4.4	8
49	What Do Patients Expect from Erectile Dysfunction Therapy?. <i>European Urology Supplements</i> , 2002 , 1, 4-11	0.9	16
48	Sildenafil citrate: lessons learned from 3 years of clinical experience. <i>International Journal of Impotence Research</i> , 2002 , 14 Suppl 1, S43-52	2.3	59
47	Current status of local penile therapy. <i>International Journal of Impotence Research</i> , 2002 , 14 Suppl 1, S70-81	2.3	37
46	Acceptance, efficacy and preference of Sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year. <i>International Journal of Impotence Research</i> , 2002 , 14, 483-6	2.3	4
45	Pharmacological management of erectile dysfunction. <i>BJU International</i> , 2003 , 91, 446-54	5.6	74
44	Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year. <i>BJU International</i> , 2003 , 92, 277-80	5.6	12
43	Hypogonadism and erectile dysfunction: the role for testosterone therapy. <i>International Journal of Impotence Research</i> , 2003 , 15 Suppl 4, S9-13	2.3	42

42	Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. <i>International Journal of Impotence Research</i> , 2003 , 15, 383-4	2.3	11
41	Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. <i>International Journal of Impotence Research</i> , 2003 , 15, 444-9	2.3	17
40	Viability and safety of combination drug therapies for erectile dysfunction. <i>Journal of Urology</i> , 2003 , 170, S20-3; discussion S23	2.5	23
39	Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. <i>Journal of Urology</i> , 2003 , 170, 159-63	2.5	130
38	Sildenafil in erectile dysfunction: a critical review. <i>Current Medical Research and Opinion</i> , 2003 , 19, 241-62.5		77
37	A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. <i>Clinical Therapeutics</i> , 2003 , 25, 2709-23	3.5	82
36	Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. <i>Clinical Therapeutics</i> , 2003 , 25, 2724-37	3.5	66
35	New achievements and pharmacotherapeutic approaches to impotence in the elderly. <i>Aging Clinical and Experimental Research</i> , 2003 , 15, 222-33	4.8	2
34	Review of tadalafil in the treatment of erectile dysfunction. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 2049-56	4	16
33	Emerging oral drugs for erectile dysfunction. <i>Expert Opinion on Emerging Drugs</i> , 2004 , 9, 179-189	3.7	4
32	Characteristics of erectile dysfunction in Saudi patients. <i>International Journal of Impotence Research</i> , 2004 , 16, 13-20	2.3	34
31	A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. <i>European Urology</i> , 2004 , 45, 499-507; discussion 507-9	10.2	76
30	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. <i>EAU Update Series</i> , 2004 , 2, 75-83		11
29	Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. <i>International Journal of Impotence Research</i> , 2005 , 17, 354-8	2.3	20
28	A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. <i>International Journal of Impotence Research</i> , 2005 , 17, 346-53	2.3	30
27	Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. <i>Clinical Cornerstone</i> , 2005 , 7, 57-65		31
26	Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy. 2005 , 253-277		1
25	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,		

24	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , 2005 , 65, 1621-50	12.1	133
23	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. <i>Actas Urológicas Españolas</i> , 2006 , 30, 67-79	0.7	7
22	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 342-349		5
21	Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. <i>Journal of Sexual Medicine</i> , 2006 , 3, 901-909	1.1	45
20	Phosphodiesterase type 5 inhibitors—extended duration of response as a variable in the treatment of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007 , 19, 119-23	2.3	27
19	Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. <i>International Journal of Impotence Research</i> , 2007 , 19, 154-60	2.3	23
18	Repeated intracorporeal self-injection: effect on peak systolic velocity and cavernosal artery diameter. <i>International Journal of Impotence Research</i> , 2007 , 19, 505-8	2.3	4
17	The substitution of Phentolamine with an equal amount of Chlormpromazine as an alpha-blocker in vasoactive cocktails used for intracavernous injection therapy for the treatment of erectile dysfunction. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2007 , 49, 14-14b	0.6	
16	Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. <i>BJU International</i> , 2007 , 100, 1313-6	5.6	19
15	Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. <i>Journal of Sexual Medicine</i> , 2007 , 4, 426-31	1.1	30
14	Contemporary Treatment of Erectile Dysfunction. 2011 ,		2
13	Targeting the glucagon receptor family for diabetes and obesity therapy. <i>Pharmacology & Therapeutics</i> , 2012 , 135, 247-78	13.9	109
12	Recruiting endogenous stem cells: a novel therapeutic approach for erectile dysfunction. <i>Asian Journal of Andrology</i> , 2016 , 18, 10-5	2.8	16
11	Contemporary Treatment of Erectile Dysfunction. <i>Contemporary Endocrinology</i> , 2016 ,	0.3	2
10	Self-Injection, Transurethral, and Topical Therapy in Erectile Dysfunction. 2016 , 187-207		1
9	SILDENAFIL VERSUS THE VACUUM ERECTION DEVICE. <i>Journal of Urology</i> , 2001 , 1779-1781	2.5	4
8	Therapie. 2002 , 129-246		
7	Erectile Dysfunction. 2005 , 193-223		

6 Self-Injection, Transurethral and Topical Therapy in Erectile Dysfunction. **2011**, 107-125

5 Erectile Dysfunction. **2015**, 65-116

4 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2016**, 83-115

3 Erectile Dysfunctions. **2020**, 75-88

2 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2020**, 85-118

1 Organ Failure and Common Disease of the Ageing Male. **2006**, 251-256

